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Cardiac transplantation is an effective therapy for end-
stage heart failure with one and five year survival rates
wx about 80% and 65% respectively 1 . Despite these good
results, cardiac allograft rejection remains a problem which
produces impaired ventricular performance and death of
cardiac myocytes ultimately causing congestive heart fail-
ure, low cardiac output, hypotension and reduced pressor
responses to catecholamines. Chronic allograft rejection
also results in the development of transplant-associated
coronary atherosclerosis, a vasculopathy that produces my-
ocardial ischemia, infarction and sudden death and is the
leading cause of death in cardiac transplant recipients after
wx the first year 2 . Although there is a large body of
evidence concerning the immunological interactions in-
volved in cardiac allograft rejection, knowledge concern-
ing the cellular and biochemical mechanisms responsible
for contractile dysfunction and for death of heart muscle
cells remains incomplete. Since an inflammatory reaction
in the myocardium is an intrinsic component of the patho-
logical changes observed during cardiac allograft rejection,
our laboratory undertook an investigation of the participa-
tion of nitric oxide synthases, particularly the inducible
. nitric oxide synthase iNOS , in the manifestations of
cardiac allograft rejection.
1. NO synthesis
The five electron oxidation of L-arginine to L-citrulline
. and biologically active nitric oxide NO is important to a
large variety of physiological and pathological processes
wx 3,4 . NO synthesis is accomplished by the three isoforms
. of NOS, the neuronal NOS nNOS, NOS 1 originally
. identified in brain, inducible NOS iNOS, NOS 2 origi-
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nally identified in macrophages and endothelial NOS
. eNOS, NOS 3 originally identified in endothelial cells.
. Constitutive nitric oxide synthases nNOS and eNOS
require calcium and calmodulin as cofactors and generate
low amounts of NO. Small amounts of NO released by
endothelial cells in response to hormones or sheer stress
interact with soluble guanylyl cyclases to increase the
formation of cyclic GMP in target cells such as platelets,
endothelial cells and vascular smooth muscle cells promot-
ing inhibition of platelet adhesion and aggregation, inhibi-
tion of leukocyte adhesion and migration and vasodilation
respectively. The NO produced by nNOS acts as a neuro-
transmitter in brain, in cells of the nonadrenergic, non-
wx cholinergic nervous system and in skeletal muscle 5 .
The inducible NO synthases expressed in macrophages,
endothelial cells, vascular smooth muscle cells and cardiac
 myocytes in response to cytokines such as IL-1b, TNF-a,
. IFN-g, IL-6 or bacterial endotoxin do not require calcium
and calmodulin as cofactors and generate substantially
wx larger amounts of NO for long periods of time 3–6 . NO
produced by iNOS in activated macrophages is cytotoxic
wx and participates in their antimicrobial actions 4,7 . NO
produced by vascular smooth muscle cells and cardiac
myocytes in response to endotoxin has been implicated in
the pathogenesis of hypotension in association with bacte-
wx rial infections 4 . The continuous large production of NO
by iNOS in cardiac myocytes has been shown to influence
myocardial contractile responses and to affect heart rate
wx 6.
Other factors important in the synthesis of NO by iNOS
include the availability of the substrate, L-arginine, and of
. w the cofactors NADPH and tetrahydrobiopterin THB 3– 4
x 7 . When iNOS is induced by cytokines in macrophages,
endothelial cells or cardiac myocytes, cationic amino acid
. transporter proteins, CAT 1, CAT 2B both high affinity
Time for primary review 29 days.
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. and CAT 2A low affinity are coinduced which can
increase the intracellular L-arginine concentration. GTP
cyclohydrolase, the key enzyme in THB biosynthesis, is 4
also coinduced with iNOS. Other experimental evidence
obtained with nNOS and iNOS indicates that NO can exert
wx a negative feedback on NO synthesis 6 . In activated
macrophages NO can inhibit iNOS activity by reducing the
availability of heme and its insertion into monomers,
blocking formation of the dimers required for enzyme
activity.
2. iNOS induction in cardiac allograft rejection
During cardiac allograft rejection there is significant
release of cytokines by activated T lymphocytes and
macrophages which participate in the immune response to
foreign HLA and other antigens present in endothelial and
wx other cells of the transplanted heart 8 . Because cytokines,
particularly those released by the Th1 subset of lympho-
cytes, were reported to stimulate iNOS expression in sev-
eral cell systems, Yang et al. used a rat model to investi-
wx gate iNOS expression during cardiac allograft rejection 9 .
Heterotopic abdominal cardiac transplantation was per-
formed using Lewis strain donor hearts and Wistar–Furth
strain recipients. Lewis to Lewis transplants were per-
formed as syngeneic controls. Allograft rejection is com-
plete at days 6–7 with this model. Cardiac allografts
examined at day 5 manifested reduced contractility and
histological changes of severe rejection, with an inflamma-
tory myocardial infiltrate composed of lymphocytes and
macrophages, edema and damage and destruction of car-
diac muscle fibers. The mRNA for iNOS and iNOS protein
were detected in ventricular homogenates and also in
isolated purified myocytes from the rejecting cardiac allo-
grafts but not in ventricular tissue or myocytes from the
syngeneic control grafts. iNOS enzyme activity and tissue
cyclic GMP levels were also increased significantly in the
rejecting allografts. Immunostaining with a highly specific
antibody indicated that iNOS protein was present in
macrophages infiltrating the myocardium and also in car-
diac myocytes of the rejecting allografts. Some lympho-
cytes and microvascular endothelial cells in the allografts
also showed positive iNOS immunostaining. The data
indicated that myocardial iNOS mRNA, protein and en-
zyme activity are induced in infiltrating macrophages and
cardiac myocytes of rejecting allografts.
Using a similar Lewis to ACI strain heterotopic rat
cardiac transplant model Worrall and coworkers confirmed
that iNOS mRNA and enzyme activity were increased in
wx rejecting cardiac allografts 10 . In agreement with a previ-
ous report serum nitriternitrate levels were also signifi-
wx cantly increased in the allograft recipients 10–12 . Im-
munostaining revealed iNOS protein in infiltrating
macrophages but not in cardiac myocytes. Whether absent
iNOS immunostaining in cardiac myocytes in the Worrall
wx studies 10,11 relates to rat strain differences, milder
rejection or methodological problems is unclear. Treatment
with aminoguanidine, a drug which inhibits iNOS activity
but which also has antioxidant properties, reduces ad-
vanced glycation end product formation and inhibits di-
. amine oxidase and aldose reductase improved allograft
papillary muscle contractile performance, reduced the ex-
tent of pathological changes and prolonged allograft sur-
wx vival from 10 to 15 days 10,11 . EPR signals in myocar-
dial tissue from the rejecting grafts were indicative of the
formation of nitrosylferromyoglobin andror nitrosylferro-
hemoglobin and of nonheme iron–dinitrosyl complexes;
these signals were also ameliorated by aminoguanidine
wx 10 . Russell et al., using a Lewis-F344 rat cardiac trans-
plantation model, also observed a prolonged increase in
expression of iNOS mRNA and immunostaining of my-
ocardial macrophages and of vascular smooth muscle cells
wx in rejecting cardiac allografts 13 . In studies of serial
endomyocardial biopsies of patients during the first year
following heart transplantation, Lewis and coworkers found
wx iNOS mRNA during the first 180 days 15 . iNOS protein
was demonstrated by immunohistochemistry in cardiac
myocytes. There was also increased myocardial cGMP.
iNOS mRNA expression was not related to the ISHLT
histological grade of rejection but was associated signifi-
cantly with systolic and diastolic dysfunction of the left
ventricle. Winlaw et al. in a study of Brown–Norway to
Lewis allografts and Lewis–Lewis isografts found that
urinary nitrite excretion in untreated allograft rejection was
increased 8 fold above basal excretion of isografts and that
peak nitrate excretion occurred early in rejection and was
wx attenuated by immunosuppressive therapy 16 .
3. iNOS in transplant vasculopathy
Allograft associated vasculopathy is considered to be a
wx form of chronic rejection 2 . Transplant associated coro-
nary artery disease tends to be diffuse, to extend to small
arteries and arterioles and to involve a proliferative intimal
response of smooth muscle cells and to a lesser extent of
macrophages. Russell et al. and Akyurek et al. reported
that eNOS was present in endothelial cells and that iNOS
expression was upregulated in macrophages and smooth
muscle cells in the intimal lesions found in rat models
wx 14,17 . Smooth muscle immunostaining was particularly
apparent at later time points in lesions from the rat. Ravalli
et al. used in-situ hybridization and immunostaining to
examine iNOS expression in human transplant coronary
wx artery disease 18 . Both iNOS mRNA and protein were
detected in neointimal macrophages, neointimal ‘foam’
cells and neointimal smooth muscle cells. Immunostaining
for nitrotyrosine was also found in the same cell types.
These findings are similar to those found in human athero-
sclerotic lesions and in mouse models of the disease
wx 19,20 . Whether iNOS expression is pathogenetic in pro-
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 moting the vascular disease e.g. by increasing oxidant
. stress and the expression of oxidant sensitive genes or is
protective against the development of vascular disease is
unclear. In the study of Aji et al. the administration of
L-arginine supplements to LDL receptor knockout mice fed
a high cholesterol diet reduced xanthoma formation and
wx the extent of atherosclerotic aortic lesions by 40% 20 .
This beneficial effect was abrogated when a NOS inhibitor
was coadministered with the L-arginine supplement sug-
gesting that NO produced by eNOS and iNOS was respon-
sible for lesion reduction. NO is known to inhibit platelet
and white cell adhesion and transmigration of white blood
cells across the endothelium and to block smooth muscle
wx cell proliferation 3,4,6 . Another possibility is that NO
contributes to vascular remodeling by its known effects to
promote apoptosis of macrophages and vascular smooth
wx muscle cells 21,22 . A recent preliminary report which
indicated that transplant associated vasculopathy was more
extensive in allografts in iNOS deficient mice is also
consistent with a protective effect of iNOS in this disorder
wx 23 .
4. Relationships of NO, cytokines and cellular immune
responses in cardiac allograft rejection
Cellular immune responses constitute major compo-
wx nents of acute and chronic allograft rejection 24 . Acti-
vated T lymphocytes, both CD4q and CD8q, along with
macrophages and endothelial cells expressing class II MHC
antigens and multiple cytokines released by macrophages
 and other cells including IL-1, IL-2, IFN-g, TNF-a, IL-6
. and IL-10 are present in the myocardium and vessels
wx undergoing allograft rejection 8,25 . iNOS expression oc-
curs early in the rejection process as reflected by immuno-
staining of myocardial tissues and also by urinary excre-
wx tion of nitriternitrate 9–11,16 . The administration of
immunosuppressive therapy such as dexamethasone, cy-
closporine A and FK506 alone or in combination resulted
in an amelioration of the pathological changes in the
myocardium and also a reduction of the levels of iNOS
. mRNA, and in another report a delay in the onset and
w peak rise in urinary excretion of nitriternitrate 9–
x 11,16,26 . As mentioned previously, the administration of
aminoguanidine, a somewhat selective iNOS inhibitor, also
resulted in an improved survival and a delay in the histo-
wx logical appearance of severe rejection 10,11 . These data
suggest that iNOS in macrophages and cardiac myocytes
plays a role in the pathogenesis of rejection but this is not
exclusive or necessarily the most important role.
The specific signal which induces iNOS expression
during allograft rejection has not been defined. Neverthe-
less, it is probable that cytokines produced by activated
wx macrophages play an important role 8,25 . Interferon-g,
TNF-a and IL-1b have been reported to induce iNOS
mRNA, protein and enzyme activity in macrophages, vas-
cular smooth muscle cells and isolated rat cardiac my-
wx ocytes in vitro 3,4,6 . It is also probable that interaction
between the CD40 ligand expressed on CD4q T-
lymphocytes and its target molecule CD40 also plays a
role. Interaction by cell contact between the CD40 ligand
on T-cells and CD40 on macrophages and has been re-
wx ported to induce iNOS in vitro 27 . In recent studies of
human coronary arteries using immunohistochemistry, Sz-
abolcs et al. found that in both transplant coronary artery
disease and atherosclerosis CD40 ligandq T-lymphocytes
were present in the intimal lesions along with abundant
positive immunostaining for CD40 on endothelial cells,
wx macrophages, ‘foam’ cells and smooth muscle cells 28 .
Larson et al. using a mouse model of heterotopic cardiac
transplantation reported that treatment with an antibody to
. CD40 ligand anti-gp39 at the time of transplantation
wx markedly prolonged graft survival 29 . Allografts from
treated recipients showed decreased expression of mRNA
for iNOS but unaltered expression of transcripts for T-cell
wx cytokines or the costimulatory molecules B7-1, B7-2 29 .
In a subsequent publication this group demonstrated that
simultaneous therapy which blocked CD40 ligand-CD40
interactions with an antibody which inhibited CD28-B7
interactions aborted T-cell clonal expansion in vitro and in
vivo and resulted in long term acceptance of cardiac and
skin allografts and inhibition of the development of coro-
wx nary vascular disease in the transplanted hearts 30 .
5. iNOS and ventricular contractile function
Impaired ventricular contractile performance and car-
diac myocyte death are the hallmarks of cardiac allograft
rejection. Much evidence suggests that NO produced by
iNOS contributes to allograft contractile dysfunction. NO
acts upon soluble guanylyl cyclase to form cyclic GMP
which is known to decrease cardiac myocyte L-type cal-
cium channel current and the contractile responses of
wx cardiac myofilaments to calcium 6,31 . Increased myocar-
dial cGMP has been found in guinea pigs treated with
wx endotoxin and in rat and human cardiac allografts 9,15,32 .
In studies by Brady et al. the amplitude of contraction of
isolated guinea pig cardiac myocytes was reduced in cells
from animals treated with endotoxin to induce iNOS and
in myocytes from normal guinea pigs that were treated
with media containing NO or the NO donor drug sodium
wx nitroprusside 32,33 . In studies of isolated rat cardiac
myocytes by Balligand, the induction of iNOS in the
myocytes by cytokines was not associated with a depres-
sion of basal contractile function but with a reduction in
the contractile responses to b adrenergic agonists that
could be reversed by administration of NOS inhibitors
wx 34,35 . Worrall et al. reported that iNOS derived NO in
 early rejection of cardiac allografts prior to widespread
. cell death was associated with impaired contractility of
isolated papillary muscles at baseline and during b adren-
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wx ergic, adenylate cyclase and calcium stimulation 10,11,36 .
wx There were also associated membrane dysfunctions 36 .
The impaired contractile responses were ameliorated by
aminoguanidine or therapy with corticosteroids which in-
hibited iNOS expression. As mentioned previously, in
studies of patients following cardiac transplantation Lewis
et al. found that iNOS mRNA was inversely related to
wx cardiac function, i.e. ejection fraction 15 . Paulus et al.
 found that in human allografts, iNOS mRNA determined
. by RT-PCR in endomyocardial biopsies was an indepen-
dent variable relating a reduced peak contractile response
to dobutamine to simultaneous shortening of systole, i.e.
there was earlier onset of left ventricular relaxation and
wx reduction of left ventricular end-systolic pressure 37 .
The mechanisms by which NO produced by iNOS
influences ventricular performance remain largely unex-
wx plored but are potentially multiple 6 . In addition to
increasing cGMP, NO can produce auto-ADP ribosylation
of glycolytic enzymes, inhibition of ribonucleotide reduc-
tase, and activation of poly ADP ribose synthetase which
can lead to depletion of cellular energy stores. NO can also
inhibit enzymes involved in the mitochondrial respiratory
chain, reducing oxygen consumption and can inhibit the
citric acid cycle enzyme aconitase. NO and its derivatives
. such as nitrososnium ion NOq can react with SH
groups to form S nitrosoproteins which can in turn support
additional transnitrosation reactions with other SH contain-
ing proteins influencing their activity. Peroxynitrite, the
product of the interaction of NO and superoxide, is a
strong oxidant which can cause autoperoxidation of lipids
and proteins and decompose to form toxic hydroxyl radi-
wx cals 38–40 . Peroxynitrite can also produce nitration of
tyrosines in cell proteins. Nitration of contractile proteins
such as actin may impede the contractile function of
wx cardiac myofilaments 40 . As will be discussed subse-
quently NO in large doses may also contribute to death of
cardiac myocytes.
6. iNOS and cardiac myocyte death
Death of cardiac myocytes is the hallmark of cardiac
allograft rejection. Because iNOS expression was apparent
in macrophages and cardiac myocytes in rejecting allo-
grafts and because the generation of NO by iNOS in
macrophages is important in the immune defenses against
invading viruses, bacteria and other microorganisms, Pin-
sky et al. performed in vitro experiments to investigate
wx potential toxic effects of NO in the heart 41 . In the first
experiments, J774 macrophages were stimulated with cy-
tokines to induce iNOS. Stimulated and control
macrophages were cocultured with isolated rat cardiac
myocytes using transwell filter inserts to prevent physical
contact between the two cell types. There was significantly
 greater myocyte death assessed by creatine kinase release
. and by trypan blue dye exclusion in cocultures with
stimulated macrophages expressing iNOS. The death rate
returned to control levels when cocultures with activated
macrophages were treated with L-NMMA which inhibits
NOS enzyme activity. The data indicated that NO pro-
duced by iNOS in activated macrophages can be lethal to
adjacent cardiac myocytes. In additional experiments they
showed that rat cardiac myocytes treated with TNF-a,
IL-1b and IFN-g expressed iNOS mRNA, protein and
enzyme activity and also exhibited a higher death rate than
wx control myocytes 41 . The increased death of cardiac
myocytes was inhibited by the administration of L-NMMA
to block NO formation and by coincubation of the stimu-
lated myocytes with TGF-b which reduced iNOS expres-
sion. The data indicate that proinflammatory cytokines can
induce iNOS expression in adult cardiac myocytes and that
NO so produced can be autotoxic to the cardiac myocytes.
Taken together the experiments suggested that NO pro-
duced by macrophages infiltrating the myocardium or by
cardiac myocytes in a cytokine rich milieu is potentially
cytotoxic to heart muscle cells. Such cardiotoxicity may be
manifest not only in allograft rejection but in other patho-
logical states such as myocardial infarction or cardiomy-
opathy in which macrophages and cytokines are abundant
and in which there is myocardial expression of iNOS.
7. Necrosis and apoptosis
Although there is considerable information concerning
immune mechanisms of cardiac myocyte death, knowledge
concerning mechanisms of myocyte death during cardiac
wx allograft rejection is incomplete 24 . During advanced
episodes of rejection there can be necrosis of heart muscle
cells. This is characterized by swelling of the cells, disrup-
tion of internal and external cell membranes and eventual
wx lysis 42 . Necrosis is often associated with a marked
inflammatory response. Recently, it has become increas-
ingly apparent that apoptosis of cardiac myocytes also
occurs in a variety of important cardiovascular diseases.
Apoptosis is a morphologically and biochemically distinct
wx form of programmed cell death 42,43 . During apoptosis
there is condensation of nuclear chromatin and cell shrink-
age with preservation of intracellular organelles. Subse-
quently there is blebbing of nuclear and cytoplasmic mem-
branes and fragmentation of the dying cell into membrane
bound ‘apoptotic’ bodies which undergo phagocytosis. The
process is relatively rapid lasting 2–12 hours. The se-
quence of events during apoptosis requires energy and
follows an internally determined program involving the
activation of endonucleases which degrade chromosomal
DNA into oligosomal fragments that are multiples of
 180–200 base pairs in lengths which form DNA ‘ladders’
. wx after electrophoresis on agarose gels 42,43 . The program
also involves the expression of multiple genes which pro-
. mote or hinder the death pathway e.g. Bcl-2 or Bax and
. the expression of genes for proteases e.g. CPP-32 in-
wx volved in cell destruction 44,45 .
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8. Apoptosis and iNOS expression in cardiac allograft
rejection
Albina and coworkers have reported that NO produced
by iNOS in cytokine-treated macrophages can trigger
apoptosis of the macrophages and also of certain tumor
wx cells cocultured with the macrophages 22,46 . Drugs that
release NO have also promoted macrophage apoptosis.
Accordingly, Szabolcs et al. used the Lewis to Wistar–
Furth heterotopic heart transplantation model to investigate
whether apoptosis occurs during cardiac allograft rejection
and whether the time course of apoptosis was related to the
wx induction of iNOS 47 . They found that significant apop-
tosis of macrophages and of cardiac myocytes occurred
during cardiac allograft rejection. Apoptosis was identified
by in situ labeling of DNA fragments in cell nuclei by two
methods and also by the presence of DNA ladders on
agarose gels. Apoptotic cardiac myocytes were distin-
guished by their characteristic striations, immunoreactivity
for muscle actin and from the appearance of intact shrunken
myocytes with intact membranes and hyperchromatic or
. fragmented nuclei Fig. 1a . In the rejecting allografts the
number of apoptotic nuclei increased sharply during days
3–5 after transplantation and at day 5 there was a signifi-
 cant increase in apoptotic nuclei macrophages, endothelial
. cells and cardiac myocytes in comparison to syngeneic
. grafts. The expression of iNOS mRNA RT-PCR , protein
and enzyme activity in the allografts paralleled in time and
extent the apoptosis of cardiac myocytes. iNOS immuno-
staining of macrophages and cardiac myocytes also in-
creased at days 3–5 and was accompanied by positive
immunostaining of cardiac muscle cells with an antibody
to nitrotyrosine which is indicative of the formation of
. peroxynitrite Fig. 1b and c . The data are compatible with
 but do not prove the hypothesis that NO andror peroxyni-
. trite can trigger apoptosis of macrophages and cardiac
myocytes in this setting. Additional mechanisms such as
interaction of cytotoxic T lymphocytes or cytokines with
the Fas protein or the activation of cysteine proteases by
granzyme-b released from CD8q T-lymphocytes may
wx also contribute to apoptosis during rejection 43,45 .
Other more recent studies have indicated that the NO-
. donor drug S-nitroso-N-acetyl-penicillamine SNAP but
not NAP triggered apoptosis of isolated rat cardiac my-
wx ocytes in vitro 48 . This effect was confirmed by identifi-
. cation of oligonucleosomal DNA fragments ‘ladders’ on
agarose gel electrophoresis and was inhibited by the addi-
tion to the incubation media of reduced hemoglobin which
scavenges NO released by the drug. Treatment with SNAP
. but not NAP or SNAP plus reduced hemoglobin was also
associated with the expression of p53, the gene product
which can be activated by DNA strand breaks to initiate
apoptosis. NO has been shown to inhibit DNA synthesis
and ribonucleotide reductase and both NO and peroxyni-
trite have been observed to cause DNA damage and strand
wx breaks 49,50 .
In order to investigate whether apoptosis and increased
expression of iNOS occur in human cardiac allograft rejec-
tion Szabolcs et al. compared right ventricular endomyo-
cardial biopsies from 30 patients with cardiac allograft
. rejection ISHLT grade 3ArB with 12 biopsies without
. rejection ISHLT grade 0 using in situ end labeling of
intranuclear DNA fragments and immunohistochemistry
wx 51 . Apoptosis of both macrophages and of cardiac my-
ocytes was observed in the rejecting allografts at a rate that
was 30 fold higher than that observed in the non-rejecting
. controls Fig. 2a . Apoptosis of myocytes was present in
both areas with macrophage-rich inflammatory infiltrates
and in areas with no inflammation. Positive immuno-
staining for iNOS was present in macrophages, mononu-
clear cells and cardiac myocytes in the rejecting allografts
. Fig. 2b . Immunostaining for nitrotyrosine, a marker of
peroxynitrite, was found in the rejecting biopsies in re-
gions where iNOS protein expression was also present
. Fig. 2c . The data indicate that apoptosis is a major form
of cardiac myocyte death during human cardiac allograft
rejection and that it occurs in association with the expres-
sion of iNOS and nitration of proteins indicative of the
presence of peroxynitrite.
9. iNOS expression in myocardial infarction and car-
diomyopathy
As discussed previously, Lewis et al. found that the
expression of iNOS mRNA in endomyocardial biopsies of
human heart transplant recipients was inversely related to
wx left ventricular performance, i.e. ejection fraction 15 .
Since apoptosis produces the gradual loss of cardiac my-
ocytes, it is possible that apoptotic myocyte loss triggered
by NO may contribute to the decline in ventricular func-
tion which is observed in many cardiac allografts over
time. iNOS has also been demonstrated in ventricular
tissues from animals with reperfusion injury or myocardial
infarction and from patients with idiopathic dilated car-
wx diomyopathy 52–56 . In addition, recent studies have
demonstrated that apoptosis of cardiac myocytes occurred
in iNOS-rich regions at the margins of acute myocardial
.  .  .  .  . Fig. 1. Rejection in rat heterotopic cardiac allograft labelled for apoptosis blue nuclei and cardiac myocytes brown cytoplasm a , iNOS brown b and
.  . . nitrotyrosine brown c . a: Cardiac myocytes brown adjacent to macrophage-rich inflammatory infiltrates show the highest rate of apoptotic nuclei
.  . blue arrow . Many apoptotic nuclei are already phagocytosed by macrophages, which prevents determination of their cellular origin. b: Numerous
. macrophages show strong reactivity for iNOS brown . Adjacent cardiac myocytes also show weak iNOS labelling. c: Nitrotyrosine which is formed after
exposure of cellular proteins to peroxynitrite is present in areas of myocyte damage and inflammation.
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wx infarctions in rabbits 52 . Other studies have indepen-
dently documented iNOS enzyme activity, iNOS mRNA
and protein in cardiac myocytes in myocardial tissues from
patients with idiopathic dilated cardiomyopathy many of
whom have elevated circulating levels of cytokines and a
macrophage-rich myocardial inflammatory infiltrate
wx 53,54 . Additional recent reports have documented that
apoptosis of cardiac myocytes occurs in ventricular tissue
from patients with idiopathic dilated cardiomyopathy who
wx died of advanced congestive heart failure 57,58 . Conceiv-
ably apoptosis of heart muscle cells triggered by iNOS
may contribute to the progression of ventricular failure in
these and other inflammatory diseases of the myocardium.
10. Possible therapeutic implications in allograft rejec-
tion and other cardiac disorders
Apoptosis of cardiac myocytes in association with iNOS
expression in allograft rejection may have several thera-
peutic implications. First, it raises the possibility that drugs
which selectively inhibit iNOS enzyme activity or which
interfere with NO production by macrophages or cardio-
cytes might be beneficial in reducing myocyte loss during
allograft rejection or other diseases such as dilated car-
diomyopathy. In a rat model, aminoguanidine, a semiselec-
tive inhibitor of NO production by iNOS but which also
has other effects, prolonged survival and reduced the
wx pathological changes in the grafts 10,11 . In preliminary
studies of our rat cardiac transplantation model, Yang et al.
administered to the allograft recipients CNI-1493, a te-
travalent guanylhydrazone compound which blocks L-
arginine transport into macrophages inhibiting iNOS syn-
thesis of NO and which also blocks the release of TNF-a
wx and other cytokines from macrophages 59–61 . In com-
parison to vehicle treated control allografts, administration
of CNI-1493 was associated with prolongation of survival,
significant reduction of apoptosis, myocyte loss and
wx macrophage infiltration of the myocardium 59 . Second,
the finding of apoptosis of cardiac myocytes in association
with iNOS raises the possibility that one could use molecu-
lar techniques such as transfection of Bcl-2 to alter the
apoptotic gene program favorably to preserve myocyte
wx viability 62 . Finally, it suggests that one might reduce
cardiac myocyte death by developing inhibitors or inacti-
. vators of the proteases caspaces such as CPP32 which
are involved in the final stages of apoptotic destruction of
wx the cardiac myocytes 63,64 .
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